WuXi Accused Of Shorting Investors In Go-Private Deal

Law360 (February 22, 2019, 3:45 PM EST) -- A putative class of investors alleged in New York federal court on Thursday that pharmaceutical research and development company WuXi PharmaTech kept them in the dark about plans to spin off subsidiaries following a $3.6 billion merger that took the company private.

A class of investors led by Altimeo Asset Management alleges that WuXi PharmaTech (Cayman) Inc. failed to disclose to investors a strategy to spin off or list three subsidiaries. The offerings and fundraising rounds raised millions and caused the company valuations to soar, ultimately dwarfing the take-private merger price.

The investors allege that the take-private offer was made by...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!